knit: (function(input_file, encoding) { out_dir <- ’’; rmarkdown::render(input_file, encoding=encoding,

output_file=file.path(dirname(input_file), out_dir, ‘index.pdf’))})

 install.packages("corrr",repos = "http://cran.us.r-project.org")
## 
## The downloaded binary packages are in
##  /var/folders/pz/q7l62sfd5938g690dfb584_80000gn/T//Rtmp1v2U1n/downloaded_packages
install.packages("SmartEDA",repos = "http://cran.us.r-project.org")
## 
## The downloaded binary packages are in
##  /var/folders/pz/q7l62sfd5938g690dfb584_80000gn/T//Rtmp1v2U1n/downloaded_packages

healthcare data - Project

Synthetic Data Generation via Gaussian Copula : SYNC

SYNC (Synthetic Data Generation via Gaussian Copula) to simulate microdata by sampling features in batches. The concept is motivated by [Copula-based approach to synthetic population generation] and [Dependence- preserving approach to synthesizing household characteristics].

The rationale behind SYNC is that features can be segmented into dis- tinct batches based on their correlations, which reduces the high dimensional problem into several sub-problems in lower dimensions.

Feature dependency in high dimensions is hard to evaluate via common methods due to its complexity and computation requirements, and as such, Gaussian copula, a family of multivariate distributions that is capable of capturing dependencies among random variables, becomes an ideal candidate for the application.

Synthetic Reconstruction (SR)

Synthetic reconstruction (SR) is the most commonly used technique to generate synthetic data. This approach reconstructs the desired distribution from survey data while constrained by the marginal distributions.

Simulated individuals are sampled from a joint distribution which is estimated by an iterative process to form a synthetic population. Typical iterative procedures used to estimate the joint distribution are iterative proportional fitting (IPF) and matrix ranking.

The IPF algorithm fits a n-dimensional contingency table base on sampled data and fixed marginal distributions. The inner cells are then scaled to match the given marginal distribution. The process is repeated until the entries converge.

IPF has many advantages like maximizing entropy, minimiz- ing discrimination information and resulting in maximum likelihood estimator of the true contingency table. However, IPF is only applicable to categorical variables.

The SYNC framework incorporates predictive models to approximate each feature, which can be used to produce real-valued outputs as well and probability distribution that can be sampled from to produce discrete features.

novel combination framework which, to the best of our knowledge, is the first published effort to combine state-of-the-art machine learning and statistical instruments (e.g., outlier detection, Gaussian copula, and predictive models) to synthesize multi source data.

SYNC’s perfor- mance as a privacy-preserving algorithm and its ability to reproduce original datasets.

SYNC as a feature engineering tool, as well as an alternative to data collection in situations where gathering is difficult through a real-world datasets in the automotive the industry

The methodology is scalable at the production level and can easily incorporate new data sources without the need to retrain the entire model.

Import data

##                                           Descriptions      Value
## 1                                   Sample size (nrow)       1221
## 2                              No. of variables (ncol)          7
## 3                    No. of numeric/interger variables          4
## 4                              No. of factor variables          0
## 5                                No. of text variables          2
## 6                             No. of logical variables          1
## 7                          No. of identifier variables          1
## 8                                No. of date variables          0
## 9             No. of zero variance variables (uniform)          1
## 10               %. of variables having complete cases 85.71% (6)
## 11   %. of variables having >0% and <50% missing cases 14.29% (1)
## 12 %. of variables having >=50% and <90% missing cases     0% (0)
## 13          %. of variables having >=90% missing cases     0% (0)
##   Index Variable_Name Variable_Type Per_of_Missing No_of_distinct_values
## 1     1             X       integer        0.00000                  1221
## 2     2         trial     character        0.00000                     1
## 3     3           trt     character        0.00000                     4
## 4     4           age       integer        0.00000                    64
## 5     5           bmi       numeric        0.00328                   248
## 6     6          male       logical        0.00000                     2
## 7     7      response       integer        0.00000                     2
##   Vname Group   TN nNeg nZero nPos NegInf PosInf NA_Value Per_of_Missing
## 2   age   All 1221    0     0 1221      0      0        0           0.00
## 3   bmi   All 1221    0     0 1217      0      0        4           0.33
## 1     X   All 1221    0     0 1221      0      0        0           0.00
##        sum  min    max   mean median     SD   CV   IQR Skewness Kurtosis   0%
## 2  56278.0 18.0   84.0  46.09   47.0  12.83 0.28  19.0     0.05    -0.47 18.0
## 3  37444.2 18.3   60.6  30.77   29.7   6.87 0.22   8.4     1.07     1.61 18.3
## 1 746031.0  1.0 1221.0 611.00  611.0 352.62 0.58 610.0     0.00    -1.20  1.0
##      10%   20%   30%   40%   50%   60%   70%   80%    90%   100% LB.25% UB.75%
## 2  29.00  35.0  39.0  43.0  47.0  49.0  53.0  57.0   63.0   84.0    8.5   84.5
## 3  23.16  25.2  26.6  27.9  29.7  31.4  33.1  35.6   39.9   60.6   13.3   46.9
## 1 123.00 245.0 367.0 489.0 611.0 733.0 855.0 977.0 1099.0 1221.0 -609.0 1831.0
##   nOutliers
## 2         0
## 3        34
## 1         0

##   Variable          Valid Frequency Percent CumPercent
## 1      trt     Etanercept       357   29.24      29.24
## 2      trt Ixekizumab Q2W       350   28.67      57.91
## 3      trt Ixekizumab Q4W       347   28.42      86.33
## 4      trt        Placebo       167   13.68     100.01
## 5      trt          TOTAL      1221      NA         NA
## 6 response              0       487   39.89      39.89
## 7 response              1       734   60.11     100.00
## 8 response          TOTAL      1221      NA         NA

##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
##  0.0000  0.0000  1.0000  0.6011  1.0000  1.0000
##   Vname Group   TN nNeg nZero nPos NegInf PosInf NA_Value Per_of_Missing
## 2   age   All 1221    0     0 1221      0      0        0           0.00
## 3   bmi   All 1221    0     0 1217      0      0        4           0.33
## 1     X   All 1221    0     0 1221      0      0        0           0.00
##        sum  min    max   mean median     SD   CV   IQR   0%    10%   20%   30%
## 2  56278.0 18.0   84.0  46.09   47.0  12.83 0.28  19.0 18.0  29.00  35.0  39.0
## 3  37444.2 18.3   60.6  30.77   29.7   6.87 0.22   8.4 18.3  23.16  25.2  26.6
## 1 746031.0  1.0 1221.0 611.00  611.0 352.62 0.58 610.0  1.0 123.00 245.0 367.0
##     40%   50%   60%   70%   80%    90%   100% LB.25% UB.75% nOutliers
## 2  43.0  47.0  49.0  53.0  57.0   63.0   84.0    8.5   84.5         0
## 3  27.9  29.7  31.4  33.1  35.6   39.9   60.6   13.3   46.9        34
## 1 489.0 611.0 733.0 855.0 977.0 1099.0 1221.0 -609.0 1831.0         0

# Variable analysis

##   VARIABLE       CATEGORY response:0 response:1 TOTAL
## 1      trt     Etanercept        216        141   357
## 2      trt Ixekizumab Q2W         30        320   350
## 3      trt Ixekizumab Q4W         78        269   347
## 4      trt        Placebo        163          4   167
## 5      trt          TOTAL        487        734  1221
## 6 response              0        487          0   487
## 7 response              1          0        734   734
## 8 response          TOTAL        487        734  1221
##   Vname        Group   TN nNeg nZero nPos NegInf PosInf NA_Value Per_of_Missing
## 2   age response:All 1221    0     0 1221      0      0        0           0.00
## 5   age   response:0  487    0     0  487      0      0        0           0.00
## 8   age   response:1  734    0     0  734      0      0        0           0.00
## 3   bmi response:All 1221    0     0 1217      0      0        4           0.33
## 6   bmi   response:0  487    0     0  485      0      0        2           0.41
## 9   bmi   response:1  734    0     0  732      0      0        2           0.27
## 1     X response:All 1221    0     0 1221      0      0        0           0.00
## 4     X   response:0  487    0     0  487      0      0        0           0.00
## 7     X   response:1  734    0     0  734      0      0        0           0.00
##        sum  min    max   mean median     SD   CV    IQR Skewness Kurtosis   0%
## 2  56278.0 18.0   84.0  46.09   47.0  12.83 0.28  19.00     0.05    -0.47 18.0
## 5  23328.0 18.0   79.0  47.90   49.0  12.68 0.26  18.00    -0.11    -0.44 18.0
## 8  32950.0 18.0   84.0  44.89   45.0  12.80 0.29  18.00     0.16    -0.41 18.0
## 3  37444.2 18.3   60.6  30.77   29.7   6.87 0.22   8.40     1.07     1.61 18.3
## 6  15410.1 18.3   60.6  31.77   30.6   7.57 0.24   9.80     1.00     1.33 18.3
## 9  22034.1 18.3   60.6  30.10   29.3   6.29 0.21   7.32     1.02     1.42 18.3
## 1 746031.0  1.0 1221.0 611.00  611.0 352.62 0.58 610.00     0.00    -1.20  1.0
## 4 309439.0  1.0 1221.0 635.40  647.0 442.15 0.70 891.00    -0.01    -1.72  1.0
## 7 436592.0  2.0 1195.0 594.81  606.5 276.89 0.47 413.50    -0.25    -0.78  2.0
##      10%    20%   30%   40%   50%    60%    70%     80%     90%   100%   LB.25%
## 2  29.00  35.00  39.0  43.0  47.0  49.00   53.0   57.00   63.00   84.0     8.50
## 5  30.00  36.20  41.0  46.0  49.0  52.00   55.0   58.00   63.40   79.0    12.00
## 8  28.00  33.00  38.0  41.0  45.0  48.00   51.0   56.00   63.00   84.0     9.00
## 3  23.16  25.20  26.6  27.9  29.7  31.40   33.1   35.60   39.90   60.6    13.30
## 6  23.24  25.48  26.8  28.7  30.6  32.70   34.6   37.36   41.08   60.6    11.30
## 9  23.10  25.00  26.4  27.7  29.3  30.56   32.3   34.56   38.49   60.6    14.79
## 1 123.00 245.00 367.0 489.0 611.0 733.00  855.0  977.00 1099.00 1221.0  -609.00
## 4  86.20 159.60 241.8 327.8 647.0 928.60 1071.2 1122.80 1171.40 1221.0 -1131.00
## 7 185.30 364.60 445.8 526.2 606.5 684.80  774.1  864.80  962.40 1195.0  -215.00
##    UB.75% nOutliers
## 2   84.50         0
## 5   84.00         0
## 8   81.00         2
## 3   46.90        34
## 6   50.50        16
## 9   44.09        25
## 1 1831.00         0
## 4 2433.00         0
## 7 1439.00         0

##   VARIABLE CATEGORY trt:Etanercept trt:Ixekizumab Q2W trt:Ixekizumab Q4W
## 1 response        0            216                 30                 78
## 2 response        1            141                320                269
## 3 response    TOTAL            357                350                347
##   trt:Placebo TOTAL
## 1         163   487
## 2           4   734
## 3         167  1221
##    Variable              Class Out_1 Out_0 TOTAL Per_1 Per_0 Odds WOE IV Ref_1
## 1     trt.1         Etanercept   357   357   714  0.29  0.29    1   0  0   Yes
## 2     trt.2     Ixekizumab Q2W   350   350   700  0.29  0.29    1   0  0   Yes
## 3     trt.3     Ixekizumab Q4W   347   347   694  0.28  0.28    1   0  0   Yes
## 4     trt.4            Placebo   167   167   334  0.14  0.14    1   0  0   Yes
## 5       X.1            [1,122]   122   122   244  0.10  0.10    1   0  0   Yes
## 6       X.2          (122,244]   122   122   244  0.10  0.10    1   0  0   Yes
## 7       X.3          (244,366]   122   122   244  0.10  0.10    1   0  0   Yes
## 8       X.4          (366,488]   122   122   244  0.10  0.10    1   0  0   Yes
## 9       X.5          (488,610]   122   122   244  0.10  0.10    1   0  0   Yes
## 10      X.6          (610,733]   123   123   246  0.10  0.10    1   0  0   Yes
## 11      X.7          (733,855]   122   122   244  0.10  0.10    1   0  0   Yes
## 12      X.8          (855,977]   122   122   244  0.10  0.10    1   0  0   Yes
## 13      X.9      (977,1.1e+03]   122   122   244  0.10  0.10    1   0  0   Yes
## 14     X.10 (1.1e+03,1.22e+03]   122   122   244  0.10  0.10    1   0  0   Yes
## 15    age.1            [18,29]   143   143   286  0.12  0.12    1   0  0   Yes
## 16    age.2            (29,35]   125   125   250  0.10  0.10    1   0  0   Yes
## 17    age.3            (35,39]   110   110   220  0.09  0.09    1   0  0   Yes
## 18    age.4            (39,43]   138   138   276  0.11  0.11    1   0  0   Yes
## 19    age.5            (43,47]   140   140   280  0.11  0.11    1   0  0   Yes
## 20    age.6            (47,49]    80    80   160  0.07  0.07    1   0  0   Yes
## 21    age.7            (49,53]   128   128   256  0.10  0.10    1   0  0   Yes
## 22    age.8            (53,57]   123   123   246  0.10  0.10    1   0  0   Yes
## 23    age.9            (57,63]   125   125   250  0.10  0.10    1   0  0   Yes
## 24   age.10            (63,84]   109   109   218  0.09  0.09    1   0  0   Yes
## 25    bmi.1        [23.1,25.2]   130   130   260  0.11  0.11    1   0  0   Yes
## 26    bmi.2        (25.2,26.6]   129   129   258  0.11  0.11    1   0  0   Yes
## 27    bmi.3        (26.6,27.9]   112   112   224  0.09  0.09    1   0  0   Yes
## 28    bmi.4        (27.9,29.7]   125   125   250  0.10  0.10    1   0  0   Yes
## 29    bmi.5        (29.7,31.4]   123   123   246  0.10  0.10    1   0  0   Yes
## 30    bmi.6        (31.4,33.1]   118   118   236  0.10  0.10    1   0  0   Yes
## 31    bmi.7        (33.1,35.6]   120   120   240  0.10  0.10    1   0  0   Yes
## 32    bmi.8        (35.6,39.9]   120   120   240  0.10  0.10    1   0  0   Yes
## 33    bmi.9               <NA>   244   244   488  0.20  0.20    1   0  0   Yes
##    Ref_0   Target
## 1   0, 1 response
## 2   0, 1 response
## 3   0, 1 response
## 4   0, 1 response
## 5   0, 1 response
## 6   0, 1 response
## 7   0, 1 response
## 8   0, 1 response
## 9   0, 1 response
## 10  0, 1 response
## 11  0, 1 response
## 12  0, 1 response
## 13  0, 1 response
## 14  0, 1 response
## 15  0, 1 response
## 16  0, 1 response
## 17  0, 1 response
## 18  0, 1 response
## 19  0, 1 response
## 20  0, 1 response
## 21  0, 1 response
## 22  0, 1 response
## 23  0, 1 response
## 24  0, 1 response
## 25  0, 1 response
## 26  0, 1 response
## 27  0, 1 response
## 28  0, 1 response
## 29  0, 1 response
## 30  0, 1 response
## 31  0, 1 response
## 32  0, 1 response
## 33  0, 1 response
##    Variable              Class Out_1 Out_0 TOTAL Per_1 Per_0 Odds WOE IV Ref_1
## 1     trt.1         Etanercept   357   357   714  0.29  0.29    1   0  0   Yes
## 2     trt.2     Ixekizumab Q2W   350   350   700  0.29  0.29    1   0  0   Yes
## 3     trt.3     Ixekizumab Q4W   347   347   694  0.28  0.28    1   0  0   Yes
## 4     trt.4            Placebo   167   167   334  0.14  0.14    1   0  0   Yes
## 5       X.1            [1,122]   122   122   244  0.10  0.10    1   0  0   Yes
## 6       X.2          (122,244]   122   122   244  0.10  0.10    1   0  0   Yes
## 7       X.3          (244,366]   122   122   244  0.10  0.10    1   0  0   Yes
## 8       X.4          (366,488]   122   122   244  0.10  0.10    1   0  0   Yes
## 9       X.5          (488,610]   122   122   244  0.10  0.10    1   0  0   Yes
## 10      X.6          (610,733]   123   123   246  0.10  0.10    1   0  0   Yes
## 11      X.7          (733,855]   122   122   244  0.10  0.10    1   0  0   Yes
## 12      X.8          (855,977]   122   122   244  0.10  0.10    1   0  0   Yes
## 13      X.9      (977,1.1e+03]   122   122   244  0.10  0.10    1   0  0   Yes
## 14     X.10 (1.1e+03,1.22e+03]   122   122   244  0.10  0.10    1   0  0   Yes
## 15    age.1            [18,29]   143   143   286  0.12  0.12    1   0  0   Yes
## 16    age.2            (29,35]   125   125   250  0.10  0.10    1   0  0   Yes
## 17    age.3            (35,39]   110   110   220  0.09  0.09    1   0  0   Yes
## 18    age.4            (39,43]   138   138   276  0.11  0.11    1   0  0   Yes
## 19    age.5            (43,47]   140   140   280  0.11  0.11    1   0  0   Yes
## 20    age.6            (47,49]    80    80   160  0.07  0.07    1   0  0   Yes
## 21    age.7            (49,53]   128   128   256  0.10  0.10    1   0  0   Yes
## 22    age.8            (53,57]   123   123   246  0.10  0.10    1   0  0   Yes
## 23    age.9            (57,63]   125   125   250  0.10  0.10    1   0  0   Yes
## 24   age.10            (63,84]   109   109   218  0.09  0.09    1   0  0   Yes
## 25    bmi.1        [23.1,25.2]   130   130   260  0.11  0.11    1   0  0   Yes
## 26    bmi.2        (25.2,26.6]   129   129   258  0.11  0.11    1   0  0   Yes
## 27    bmi.3        (26.6,27.9]   112   112   224  0.09  0.09    1   0  0   Yes
## 28    bmi.4        (27.9,29.7]   125   125   250  0.10  0.10    1   0  0   Yes
## 29    bmi.5        (29.7,31.4]   123   123   246  0.10  0.10    1   0  0   Yes
## 30    bmi.6        (31.4,33.1]   118   118   236  0.10  0.10    1   0  0   Yes
## 31    bmi.7        (33.1,35.6]   120   120   240  0.10  0.10    1   0  0   Yes
## 32    bmi.8        (35.6,39.9]   120   120   240  0.10  0.10    1   0  0   Yes
## 33    bmi.9               <NA>   244   244   488  0.20  0.20    1   0  0   Yes
##    Ref_0   Target
## 1   0, 1 response
## 2   0, 1 response
## 3   0, 1 response
## 4   0, 1 response
## 5   0, 1 response
## 6   0, 1 response
## 7   0, 1 response
## 8   0, 1 response
## 9   0, 1 response
## 10  0, 1 response
## 11  0, 1 response
## 12  0, 1 response
## 13  0, 1 response
## 14  0, 1 response
## 15  0, 1 response
## 16  0, 1 response
## 17  0, 1 response
## 18  0, 1 response
## 19  0, 1 response
## 20  0, 1 response
## 21  0, 1 response
## 22  0, 1 response
## 23  0, 1 response
## 24  0, 1 response
## 25  0, 1 response
## 26  0, 1 response
## 27  0, 1 response
## 28  0, 1 response
## 29  0, 1 response
## 30  0, 1 response
## 31  0, 1 response
## 32  0, 1 response
## 33  0, 1 response
##    Variable              Class Out_1 Out_0 TOTAL Per_1 Per_0 Odds WOE IV Ref_1
## 1     trt.1         Etanercept   357   357   714  0.29  0.29    1   0  0   Yes
## 2     trt.2     Ixekizumab Q2W   350   350   700  0.29  0.29    1   0  0   Yes
## 3     trt.3     Ixekizumab Q4W   347   347   694  0.28  0.28    1   0  0   Yes
## 4     trt.4            Placebo   167   167   334  0.14  0.14    1   0  0   Yes
## 5       X.1            [1,122]   122   122   244  0.10  0.10    1   0  0   Yes
## 6       X.2          (122,244]   122   122   244  0.10  0.10    1   0  0   Yes
## 7       X.3          (244,366]   122   122   244  0.10  0.10    1   0  0   Yes
## 8       X.4          (366,488]   122   122   244  0.10  0.10    1   0  0   Yes
## 9       X.5          (488,610]   122   122   244  0.10  0.10    1   0  0   Yes
## 10      X.6          (610,733]   123   123   246  0.10  0.10    1   0  0   Yes
## 11      X.7          (733,855]   122   122   244  0.10  0.10    1   0  0   Yes
## 12      X.8          (855,977]   122   122   244  0.10  0.10    1   0  0   Yes
## 13      X.9      (977,1.1e+03]   122   122   244  0.10  0.10    1   0  0   Yes
## 14     X.10 (1.1e+03,1.22e+03]   122   122   244  0.10  0.10    1   0  0   Yes
## 15    age.1            [18,29]   143   143   286  0.12  0.12    1   0  0   Yes
## 16    age.2            (29,35]   125   125   250  0.10  0.10    1   0  0   Yes
## 17    age.3            (35,39]   110   110   220  0.09  0.09    1   0  0   Yes
## 18    age.4            (39,43]   138   138   276  0.11  0.11    1   0  0   Yes
## 19    age.5            (43,47]   140   140   280  0.11  0.11    1   0  0   Yes
## 20    age.6            (47,49]    80    80   160  0.07  0.07    1   0  0   Yes
## 21    age.7            (49,53]   128   128   256  0.10  0.10    1   0  0   Yes
## 22    age.8            (53,57]   123   123   246  0.10  0.10    1   0  0   Yes
## 23    age.9            (57,63]   125   125   250  0.10  0.10    1   0  0   Yes
## 24   age.10            (63,84]   109   109   218  0.09  0.09    1   0  0   Yes
## 25    bmi.1        [23.1,25.2]   130   130   260  0.11  0.11    1   0  0   Yes
## 26    bmi.2        (25.2,26.6]   129   129   258  0.11  0.11    1   0  0   Yes
## 27    bmi.3        (26.6,27.9]   112   112   224  0.09  0.09    1   0  0   Yes
## 28    bmi.4        (27.9,29.7]   125   125   250  0.10  0.10    1   0  0   Yes
## 29    bmi.5        (29.7,31.4]   123   123   246  0.10  0.10    1   0  0   Yes
## 30    bmi.6        (31.4,33.1]   118   118   236  0.10  0.10    1   0  0   Yes
## 31    bmi.7        (33.1,35.6]   120   120   240  0.10  0.10    1   0  0   Yes
## 32    bmi.8        (35.6,39.9]   120   120   240  0.10  0.10    1   0  0   Yes
## 33    bmi.9               <NA>   244   244   488  0.20  0.20    1   0  0   Yes
##    Ref_0   Target
## 1   0, 1 response
## 2   0, 1 response
## 3   0, 1 response
## 4   0, 1 response
## 5   0, 1 response
## 6   0, 1 response
## 7   0, 1 response
## 8   0, 1 response
## 9   0, 1 response
## 10  0, 1 response
## 11  0, 1 response
## 12  0, 1 response
## 13  0, 1 response
## 14  0, 1 response
## 15  0, 1 response
## 16  0, 1 response
## 17  0, 1 response
## 18  0, 1 response
## 19  0, 1 response
## 20  0, 1 response
## 21  0, 1 response
## 22  0, 1 response
## 23  0, 1 response
## 24  0, 1 response
## 25  0, 1 response
## 26  0, 1 response
## 27  0, 1 response
## 28  0, 1 response
## 29  0, 1 response
## 30  0, 1 response
## 31  0, 1 response
## 32  0, 1 response
## 33  0, 1 response

## $outlier_summary
##              Category   age
## 1     Lower cap : 0.1    29
## 2     Upper cap : 0.9    63
## 3         Lower bound   8.5
## 4         Upper bound  84.5
## 5     Num of outliers     0
## 6  Lower outlier case      
## 7  Upper outlier case      
## 8         Mean before 46.09
## 9          Mean after 46.09
## 10      Median before    47
## 11       Median after    47
##                                                                                                                                           bmi
## 1                                                                                                                                       23.16
## 2                                                                                                                                        39.9
## 3                                                                                                                                        13.3
## 4                                                                                                                                        46.9
## 5                                                                                                                                          38
## 6                                                                                                                                            
## 7  34,57,139,154,158,200,215,258,302,316,330,347,353,422,442,445,447,501,545,605,617,654,671,677,694,711,746,798,804,1004,1091,1183,1209,1218
## 8                                                                                                                                       30.77
## 9                                                                                                                                       30.16
## 10                                                                                                                                       29.7
## 11                                                                                                                                       29.5
## 
## $outlier_data
##          X     trial        trt age  bmi  male response out_cap_bmi out_imp_bmi
##    1:    1 UNCOVER-2 Etanercept  51 34.5  TRUE        0        34.5       34.50
##    2:    2 UNCOVER-2 Etanercept  64 24.2  TRUE        1        24.2       24.20
##    3:    3 UNCOVER-2 Etanercept  59 26.1  TRUE        1        26.1       26.10
##    4:    4 UNCOVER-2 Etanercept  54 19.7  TRUE        0        19.7       19.70
##    5:    5 UNCOVER-2 Etanercept  50 30.3  TRUE        0        30.3       30.30
##   ---                                                                          
## 1217: 1217 UNCOVER-2    Placebo  49 40.7 FALSE        0        40.7       40.70
## 1218: 1218 UNCOVER-2    Placebo  46 60.6 FALSE        0        39.9       30.16
## 1219: 1219 UNCOVER-2    Placebo  57 32.3  TRUE        0        32.3       32.30
## 1220: 1220 UNCOVER-2    Placebo  31 21.3  TRUE        0        21.3       21.30
## 1221: 1221 UNCOVER-2    Placebo  65 27.8 FALSE        0        27.8       27.80
## 
## $outlier_index
## $outlier_index$upper_out_index
## $outlier_index$upper_out_index$age
## numeric(0)
## 
## $outlier_index$upper_out_index$bmi
##  [1]   34   57  139  154  158  200  215  258  302  316  330  347  353  422  442  445  447  501  545  605  617  654  671  677  694  711  746  798  804
## [30] 1004 1091 1183 1209 1218
## 
## 
## $outlier_index$lower_out_index
## $outlier_index$lower_out_index$age
## numeric(0)
## 
## $outlier_index$lower_out_index$bmi
## numeric(0)
## $outlier_summary
##              Category   age                                                       bmi
## 1     Lower cap : 0.1    29                                                     23.16
## 2     Upper cap : 0.9    63                                                      39.9
## 3         Lower bound   7.6                                                     10.14
## 4         Upper bound 84.59                                                     51.39
## 5     Num of outliers     0                                                        18
## 6  Lower outlier case                                                                
## 7  Upper outlier case       34,158,200,258,422,445,501,617,677,694,746,1091,1183,1218
## 8         Mean before 46.09                                                     30.77
## 9          Mean after 46.09                                                     30.47
## 10      Median before    47                                                      29.7
## 11       Median after    47                                                      29.6
## 
## $outlier_data
##          X     trial        trt age  bmi  male response out_cap_bmi out_imp_bmi
##    1:    1 UNCOVER-2 Etanercept  51 34.5  TRUE        0        34.5        34.5
##    2:    2 UNCOVER-2 Etanercept  64 24.2  TRUE        1        24.2        24.2
##    3:    3 UNCOVER-2 Etanercept  59 26.1  TRUE        1        26.1        26.1
##    4:    4 UNCOVER-2 Etanercept  54 19.7  TRUE        0        19.7        19.7
##    5:    5 UNCOVER-2 Etanercept  50 30.3  TRUE        0        30.3        30.3
##   ---                                                                          
## 1217: 1217 UNCOVER-2    Placebo  49 40.7 FALSE        0        40.7        40.7
## 1218: 1218 UNCOVER-2    Placebo  46 60.6 FALSE        0        39.9        29.6
## 1219: 1219 UNCOVER-2    Placebo  57 32.3  TRUE        0        32.3        32.3
## 1220: 1220 UNCOVER-2    Placebo  31 21.3  TRUE        0        21.3        21.3
## 1221: 1221 UNCOVER-2    Placebo  65 27.8 FALSE        0        27.8        27.8
## 
## $outlier_index
## $outlier_index$upper_out_index
## $outlier_index$upper_out_index$age
## numeric(0)
## 
## $outlier_index$upper_out_index$bmi
##  [1]   34  158  200  258  422  445  501  617  677  694  746 1091 1183 1218
## 
## 
## $outlier_index$lower_out_index
## $outlier_index$lower_out_index$age
## numeric(0)
## 
## $outlier_index$lower_out_index$bmi
## numeric(0)
##          X     trial        trt age  bmi  male response
##    1:    1 UNCOVER-2 Etanercept  51 34.5  TRUE        0
##    2:    2 UNCOVER-2 Etanercept  64 24.2  TRUE        1
##    3:    3 UNCOVER-2 Etanercept  59 26.1  TRUE        1
##    4:    4 UNCOVER-2 Etanercept  54 19.7  TRUE        0
##    5:    5 UNCOVER-2 Etanercept  50 30.3  TRUE        0
##   ---                                                  
## 1217: 1217 UNCOVER-2    Placebo  49 40.7 FALSE        0
## 1218: 1218 UNCOVER-2    Placebo  46 60.6 FALSE        0
## 1219: 1219 UNCOVER-2    Placebo  57 32.3  TRUE        0
## 1220: 1220 UNCOVER-2    Placebo  31 21.3  TRUE        0
## 1221: 1221 UNCOVER-2    Placebo  65 27.8 FALSE        0
## Classes 'data.table' and 'data.frame':   1221 obs. of  7 variables:
##  $ X       : int  1 2 3 4 5 6 7 8 9 10 ...
##  $ trial   : chr  "UNCOVER-2" "UNCOVER-2" "UNCOVER-2" "UNCOVER-2" ...
##  $ trt     : chr  "Etanercept" "Etanercept" "Etanercept" "Etanercept" ...
##  $ age     : int  51 64 59 54 50 57 36 54 50 26 ...
##  $ bmi     : num  34.5 24.2 26.1 19.7 30.3 25.8 30.3 38.1 30.3 27.2 ...
##  $ male    : logi  TRUE TRUE TRUE TRUE TRUE TRUE ...
##  $ response: int  0 1 1 0 0 1 0 1 0 1 ...

trial, trt are characters age: int bmi : numeric male: logical

response : int

##        X    trial      trt      age      bmi     male response 
##     1221        1        4       64      248        2        2
##   n_distinct     class
## 1       1221   integer
## 2          1 character
## 3          4 character
## 4         64   integer
## 5        248   numeric
## 6          2   logical
## 7          2   integer
##     X     trial        trt age  bmi  male response
## 1: 10 UNCOVER-2 Etanercept  26 27.2  TRUE        1
## 2: 11 UNCOVER-2 Etanercept  61 31.5  TRUE        0
## 3: 12 UNCOVER-2 Etanercept  29 23.4 FALSE        0
## 4: 13 UNCOVER-2 Etanercept  52 27.5 FALSE        1
## 5: 14 UNCOVER-2 Etanercept  42 22.7 FALSE        1
## 6: 15 UNCOVER-2 Etanercept  58 34.6  TRUE        0
##       X     trial     trt age  bmi  male response
## 1: 1091 UNCOVER-2 Placebo  46 60.6  TRUE        1
## 2: 1183 UNCOVER-2 Placebo  46 60.6  TRUE        0
## 3: 1218 UNCOVER-2 Placebo  46 60.6 FALSE        0
##   X trial trt age bmi male response
## 1 0     0   0   0   4    0        0
## [1] 4

Categorical variable

Numeric variable

Logical variable

##     vars    n   mean     sd median trimmed    mad  min    max  range skew kurtosis    se
## X      1 1221 611.00 352.62  611.0  611.00 452.19  1.0 1221.0 1220.0 0.00    -1.20 10.09
## bmi    2 1217  30.77   6.87   29.7   30.10   6.08 18.3   60.6   42.3 1.06     1.60  0.20
## age    3 1221  46.09  12.83   47.0   46.06  13.34 18.0   84.0   66.0 0.05    -0.47  0.37
##     vars trimmed   mean skew     sd  range
## X      1  611.00 611.00 0.00 352.62 1220.0
## age    3   46.06  46.09 0.05  12.83   66.0
## bmi    2   30.10  30.77 1.06   6.87   42.3
## # A tibble: 1,221 x 3
##        X   bmi   age
##    <int> <dbl> <int>
##  1     1  34.5    51
##  2     2  24.2    64
##  3     3  26.1    59
##  4     4  19.7    54
##  5     5  30.3    50
##  6     6  25.8    57
##  7     7  30.3    36
##  8     8  38.1    54
##  9     9  30.3    50
## 10    10  27.2    26
## # … with 1,211 more rows
## 
##  Anderson-Darling normality test
## 
## data:  num_var$bmi
## A = 15.796, p-value < 2.2e-16
## 
##  Anderson-Darling normality test
## 
## data:  num_var$age
## A = 1.6496, p-value = 0.00031
## 
##  Shapiro-Wilk normality test
## 
## data:  num_var$bmi
## W = 0.93986, p-value < 2.2e-16
## 
##  Shapiro-Wilk normality test
## 
## data:  num_var$age
## W = 0.99285, p-value = 1.244e-05

## # A tibble: 3 x 4
##   term        X     bmi     age
##   <chr>   <dbl>   <dbl>   <dbl>
## 1 X     NA      -0.0243 -0.0609
## 2 bmi   -0.0243 NA       0.139 
## 3 age   -0.0609  0.139  NA

## # A tibble: 1,221 x 4
## # Groups:   X, bmi [1,221]
##        X   bmi trt            n
##    <int> <dbl> <fct>      <int>
##  1     1  34.5 Etanercept     1
##  2     2  24.2 Etanercept     1
##  3     3  26.1 Etanercept     1
##  4     4  19.7 Etanercept     1
##  5     5  30.3 Etanercept     1
##  6     6  25.8 Etanercept     1
##  7     7  30.3 Etanercept     1
##  8     8  38.1 Etanercept     1
##  9     9  30.3 Etanercept     1
## 10    10  27.2 Etanercept     1
## # … with 1,211 more rows

##   variable n_distinct     class
## 1        X       1221   integer
## 2    trial          1 character
## 3      trt          4 character
## 4      age         64   integer
## 5      bmi        248   numeric
## 6     male          2   logical
## 7 response          2   integer
## # A tibble: 1,221 x 4
## # Groups:   X, bmi [1,221]
##        X trt          bmi male 
##    <int> <chr>      <dbl> <lgl>
##  1     1 Etanercept  34.5 TRUE 
##  2     2 Etanercept  24.2 TRUE 
##  3     3 Etanercept  26.1 TRUE 
##  4     4 Etanercept  19.7 TRUE 
##  5     5 Etanercept  30.3 TRUE 
##  6     6 Etanercept  25.8 TRUE 
##  7     7 Etanercept  30.3 TRUE 
##  8     8 Etanercept  38.1 FALSE
##  9     9 Etanercept  30.3 FALSE
## 10    10 Etanercept  27.2 TRUE 
## # … with 1,211 more rows

X bmi trt n
1 34.5 Etanercept 1
2 24.2 Etanercept 1
3 26.1 Etanercept 1
4 19.7 Etanercept 1
5 30.3 Etanercept 1
6 25.8 Etanercept 1
7 30.3 Etanercept 1
8 38.1 Etanercept 1
9 30.3 Etanercept 1
10 27.2 Etanercept 1
11 31.5 Etanercept 1
12 23.4 Etanercept 1
13 27.5 Etanercept 1
14 22.7 Etanercept 1
15 34.6 Etanercept 1
16 22.6 Etanercept 1
17 41.9 Etanercept 1
18 45.2 Etanercept 1
19 28.1 Etanercept 1
20 30.2 Etanercept 1
21 25.1 Etanercept 1
22 28.9 Etanercept 1
23 27.3 Etanercept 1
24 25.8 Etanercept 1
25 40.3 Etanercept 1
26 28.7 Etanercept 1
27 31.1 Etanercept 1
28 30.0 Etanercept 1
29 39.2 Etanercept 1
30 19.8 Etanercept 1
31 35.6 Etanercept 1
32 38.8 Etanercept 1
33 30.2 Etanercept 1
34 56.9 Etanercept 1
35 43.5 Etanercept 1
36 36.6 Etanercept 1
37 22.6 Etanercept 1
38 23.4 Etanercept 1
39 31.7 Etanercept 1
40 28.7 Etanercept 1
41 24.5 Etanercept 1
42 23.9 Etanercept 1
43 29.0 Etanercept 1
44 31.9 Etanercept 1
45 35.8 Etanercept 1
46 24.2 Etanercept 1
47 24.2 Etanercept 1
48 30.3 Etanercept 1
49 45.6 Etanercept 1
50 26.3 Etanercept 1
51 40.7 Etanercept 1
52 26.3 Etanercept 1
53 38.1 Etanercept 1
54 23.5 Etanercept 1
55 25.0 Etanercept 1
56 26.6 Etanercept 1
57 48.5 Etanercept 1
58 29.5 Etanercept 1
59 36.6 Etanercept 1
60 35.4 Etanercept 1
61 41.4 Etanercept 1
62 26.8 Etanercept 1
63 38.2 Etanercept 1
64 31.1 Etanercept 1
65 30.5 Etanercept 1
66 26.9 Etanercept 1
67 27.4 Etanercept 1
68 25.1 Etanercept 1
69 33.0 Etanercept 1
70 35.4 Etanercept 1
71 36.0 Etanercept 1
72 31.8 Etanercept 1
73 29.8 Etanercept 1
74 27.3 Etanercept 1
75 26.3 Etanercept 1
76 27.3 Etanercept 1
77 34.2 Etanercept 1
78 25.8 Etanercept 1
79 24.4 Etanercept 1
80 45.2 Etanercept 1
81 24.2 Etanercept 1
82 24.8 Etanercept 1
83 25.5 Etanercept 1
84 35.1 Etanercept 1
85 38.2 Etanercept 1
86 27.3 Etanercept 1
87 36.3 Etanercept 1
88 21.6 Etanercept 1
89 40.7 Etanercept 1
90 30.0 Etanercept 1
91 21.1 Etanercept 1
92 36.0 Etanercept 1
93 31.7 Etanercept 1
94 29.9 Etanercept 1
95 35.4 Etanercept 1
96 39.5 Etanercept 1
97 30.9 Etanercept 1
98 25.8 Etanercept 1
99 35.7 Etanercept 1
100 27.5 Etanercept 1
101 28.7 Etanercept 1
102 31.4 Etanercept 1
103 25.9 Etanercept 1
104 30.8 Etanercept 1
105 33.9 Etanercept 1
106 30.5 Etanercept 1
107 26.8 Etanercept 1
108 22.6 Etanercept 1
109 40.5 Etanercept 1
110 23.5 Etanercept 1
111 21.1 Etanercept 1
112 27.8 Etanercept 1
113 39.9 Etanercept 1
114 28.7 Etanercept 1
115 25.9 Etanercept 1
116 25.2 Etanercept 1
117 29.5 Etanercept 1
118 31.6 Etanercept 1
119 36.0 Etanercept 1
120 27.3 Etanercept 1
121 39.5 Etanercept 1
122 22.2 Etanercept 1
123 42.5 Etanercept 1
124 34.5 Etanercept 1
125 30.8 Etanercept 1
126 29.7 Etanercept 1
127 31.5 Etanercept 1
128 31.4 Etanercept 1
129 34.9 Etanercept 1
130 33.9 Etanercept 1
131 26.7 Etanercept 1
132 24.6 Etanercept 1
133 39.3 Etanercept 1
134 30.9 Etanercept 1
135 25.9 Etanercept 1
136 25.7 Etanercept 1
137 31.1 Etanercept 1
138 28.3 Etanercept 1
139 48.5 Etanercept 1
140 28.6 Etanercept 1
141 26.0 Etanercept 1
142 31.7 Etanercept 1
143 38.9 Etanercept 1
144 45.3 Etanercept 1
145 31.1 Etanercept 1
146 24.2 Etanercept 1
147 31.2 Etanercept 1
148 29.3 Etanercept 1
149 19.7 Etanercept 1
150 24.0 Etanercept 1
151 28.4 Etanercept 1
152 36.3 Etanercept 1
153 35.1 Etanercept 1
154 50.6 Etanercept 1
155 36.9 Etanercept 1
156 28.4 Etanercept 1
157 31.7 Etanercept 1
158 56.9 Etanercept 1
159 21.1 Etanercept 1
160 25.2 Etanercept 1
161 35.4 Etanercept 1
162 26.8 Etanercept 1
163 46.8 Etanercept 1
164 28.0 Etanercept 1
165 40.7 Etanercept 1
166 41.9 Etanercept 1
167 30.8 Etanercept 1
168 36.0 Etanercept 1
169 35.0 Etanercept 1
170 32.4 Etanercept 1
171 33.9 Etanercept 1
172 36.6 Etanercept 1
173 33.1 Etanercept 1
174 44.7 Etanercept 1
175 26.1 Etanercept 1
176 35.8 Etanercept 1
177 35.6 Etanercept 1
178 22.0 Etanercept 1
179 25.7 Etanercept 1
180 24.3 Etanercept 1
181 31.4 Etanercept 1
182 26.3 Etanercept 1
183 38.8 Etanercept 1
184 25.4 Etanercept 1
185 24.0 Etanercept 1
186 29.0 Etanercept 1
187 28.7 Etanercept 1
188 31.5 Etanercept 1
189 23.4 Etanercept 1
190 26.8 Etanercept 1
191 29.7 Etanercept 1
192 26.0 Etanercept 1
193 31.7 Etanercept 1
194 30.8 Etanercept 1
195 27.5 Etanercept 1
196 27.6 Etanercept 1
197 41.2 Etanercept 1
198 23.8 Etanercept 1
199 34.3 Etanercept 1
200 51.5 Etanercept 1
201 32.0 Etanercept 1
202 43.8 Etanercept 1
203 21.1 Etanercept 1
204 27.3 Etanercept 1
205 26.1 Etanercept 1
206 30.0 Etanercept 1
207 33.2 Etanercept 1
208 38.3 Etanercept 1
209 28.4 Etanercept 1
210 31.0 Etanercept 1
211 32.7 Etanercept 1
212 35.6 Etanercept 1
213 25.3 Etanercept 1
214 21.8 Etanercept 1
215 50.6 Etanercept 1
216 36.9 Etanercept 1
217 44.8 Etanercept 1
218 24.2 Etanercept 1
219 26.8 Etanercept 1
220 26.3 Etanercept 1
221 23.5 Etanercept 1
222 20.7 Etanercept 1
223 25.5 Etanercept 1
224 40.7 Etanercept 1
225 30.5 Etanercept 1
226 33.9 Etanercept 1
227 28.0 Etanercept 1
228 25.2 Etanercept 1
229 27.2 Etanercept 1
230 30.8 Etanercept 1
231 29.7 Etanercept 1
232 23.5 Etanercept 1
233 30.4 Etanercept 1
234 33.5 Etanercept 1
235 24.2 Etanercept 1
236 30.3 Etanercept 1
237 20.0 Etanercept 1
238 28.2 Etanercept 1
239 25.2 Etanercept 1
240 43.3 Etanercept 1
241 28.0 Etanercept 1
242 31.7 Etanercept 1
243 30.1 Etanercept 1
244 40.7 Etanercept 1
245 39.3 Etanercept 1
246 37.9 Etanercept 1
247 37.8 Etanercept 1
248 22.9 Etanercept 1
249 38.2 Etanercept 1
250 35.1 Etanercept 1
251 28.4 Etanercept 1
252 29.7 Etanercept 1
253 45.2 Etanercept 1
254 26.3 Etanercept 1
255 40.4 Etanercept 1
256 41.2 Etanercept 1
257 39.7 Etanercept 1
258 58.6 Etanercept 1
259 25.0 Etanercept 1
260 24.5 Etanercept 1
261 25.8 Etanercept 1
262 24.2 Etanercept 1
263 30.1 Etanercept 1
264 29.1 Etanercept 1
265 26.6 Etanercept 1
266 24.2 Etanercept 1
267 25.1 Etanercept 1
268 28.2 Etanercept 1
269 21.2 Etanercept 1
270 34.3 Etanercept 1
271 41.9 Etanercept 1
272 27.3 Etanercept 1
273 41.9 Etanercept 1
274 26.1 Etanercept 1
275 34.6 Etanercept 1
276 27.3 Etanercept 1
277 27.9 Etanercept 1
278 38.3 Etanercept 1
279 25.7 Etanercept 1
280 35.7 Etanercept 1
281 33.2 Etanercept 1
282 30.3 Etanercept 1
283 26.9 Etanercept 1
284 26.0 Etanercept 1
285 26.3 Etanercept 1
286 46.8 Etanercept 1
287 27.5 Etanercept 1
288 33.9 Etanercept 1
289 34.1 Etanercept 1
290 27.2 Etanercept 1
291 45.1 Etanercept 1
292 23.3 Etanercept 1
293 41.2 Etanercept 1
294 29.7 Etanercept 1
295 21.1 Etanercept 1
296 35.4 Etanercept 1
297 24.2 Etanercept 1
298 32.3 Etanercept 1
299 39.7 Etanercept 1
300 21.1 Etanercept 1
301 27.6 Etanercept 1
302 51.0 Etanercept 1
303 33.6 Etanercept 1
304 24.9 Etanercept 1
305 22.1 Etanercept 1
306 39.5 Etanercept 1
307 23.6 Etanercept 1
308 43.5 Etanercept 1
309 35.0 Etanercept 1
310 34.9 Etanercept 1
311 31.6 Etanercept 1
312 29.3 Etanercept 1
313 27.3 Etanercept 1
314 38.3 Etanercept 1
315 28.0 Etanercept 1
316 50.6 Etanercept 1
317 26.6 Etanercept 1
318 31.3 Etanercept 1
319 36.3 Etanercept 1
320 23.5 Etanercept 1
321 22.3 Etanercept 1
322 33.4 Etanercept 1
323 34.5 Etanercept 1
324 36.3 Etanercept 1
325 29.3 Etanercept 1
326 30.5 Etanercept 1
327 26.1 Etanercept 1
328 29.9 Etanercept 1
329 21.1 Etanercept 1
330 47.8 Etanercept 1
331 39.3 Etanercept 1
332 23.6 Etanercept 1
333 24.3 Etanercept 1
334 25.2 Etanercept 1
335 35.4 Etanercept 1
336 27.7 Etanercept 1
337 23.5 Etanercept 1
338 33.9 Etanercept 1
339 27.8 Etanercept 1
340 25.2 Etanercept 1
341 29.0 Etanercept 1
342 31.2 Etanercept 1
343 23.1 Etanercept 1
344 27.3 Etanercept 1
345 40.4 Etanercept 1
346 41.2 Etanercept 1
347 51.0 Etanercept 1
348 35.3 Etanercept 1
349 25.9 Etanercept 1
350 24.5 Etanercept 1
351 33.1 Etanercept 1
352 24.0 Etanercept 1
353 49.6 Etanercept 1
354 28.4 Etanercept 1
355 29.9 Etanercept 1
356 34.6 Etanercept 1
357 27.8 Etanercept 1
358 42.7 Ixekizumab Q2W 1
359 29.8 Ixekizumab Q2W 1
360 20.5 Ixekizumab Q2W 1
361 29.4 Ixekizumab Q2W 1
362 38.7 Ixekizumab Q2W 1
363 24.1 Ixekizumab Q2W 1
364 32.6 Ixekizumab Q2W 1
365 24.1 Ixekizumab Q2W 1
366 23.3 Ixekizumab Q2W 1
367 28.1 Ixekizumab Q2W 1
368 29.0 Ixekizumab Q2W 1
369 27.5 Ixekizumab Q2W 1
370 27.7 Ixekizumab Q2W 1
371 23.2 Ixekizumab Q2W 1
372 36.0 Ixekizumab Q2W 1
373 36.0 Ixekizumab Q2W 1
374 25.3 Ixekizumab Q2W 1
375 30.8 Ixekizumab Q2W 1
376 30.1 Ixekizumab Q2W 1
377 25.3 Ixekizumab Q2W 1
378 30.7 Ixekizumab Q2W 1
379 26.1 Ixekizumab Q2W 1
380 25.6 Ixekizumab Q2W 1
381 33.8 Ixekizumab Q2W 1
382 27.9 Ixekizumab Q2W 1
383 33.5 Ixekizumab Q2W 1
384 24.8 Ixekizumab Q2W 1
385 32.8 Ixekizumab Q2W 1
386 31.2 Ixekizumab Q2W 1
387 25.0 Ixekizumab Q2W 1
388 34.9 Ixekizumab Q2W 1
389 26.5 Ixekizumab Q2W 1
390 28.7 Ixekizumab Q2W 1
391 35.2 Ixekizumab Q2W 1
392 25.4 Ixekizumab Q2W 1
393 32.6 Ixekizumab Q2W 1
394 28.1 Ixekizumab Q2W 1
395 30.1 Ixekizumab Q2W 1
396 32.5 Ixekizumab Q2W 1
397 23.5 Ixekizumab Q2W 1
398 21.5 Ixekizumab Q2W 1
399 30.7 Ixekizumab Q2W 1
400 27.5 Ixekizumab Q2W 1
401 23.0 Ixekizumab Q2W 1
402 21.1 Ixekizumab Q2W 1
403 19.9 Ixekizumab Q2W 1
404 34.2 Ixekizumab Q2W 1
405 33.5 Ixekizumab Q2W 1
406 38.7 Ixekizumab Q2W 1
407 40.4 Ixekizumab Q2W 1
408 30.8 Ixekizumab Q2W 1
409 28.1 Ixekizumab Q2W 1
410 31.1 Ixekizumab Q2W 1
411 27.3 Ixekizumab Q2W 1
412 33.0 Ixekizumab Q2W 1
413 21.2 Ixekizumab Q2W 1
414 28.4 Ixekizumab Q2W 1
415 44.1 Ixekizumab Q2W 1
416 22.7 Ixekizumab Q2W 1
417 22.7 Ixekizumab Q2W 1
418 26.8 Ixekizumab Q2W 1
419 26.0 Ixekizumab Q2W 1
420 44.0 Ixekizumab Q2W 1
421 29.8 Ixekizumab Q2W 1
422 54.0 Ixekizumab Q2W 1
423 42.3 Ixekizumab Q2W 1
424 22.3 Ixekizumab Q2W 1
425 21.7 Ixekizumab Q2W 1
426 42.7 Ixekizumab Q2W 1
427 37.3 Ixekizumab Q2W 1
428 23.2 Ixekizumab Q2W 1
429 32.7 Ixekizumab Q2W 1
430 27.7 Ixekizumab Q2W 1
431 26.5 Ixekizumab Q2W 1
432 31.6 Ixekizumab Q2W 1
433 23.5 Ixekizumab Q2W 1
434 33.0 Ixekizumab Q2W 1
435 26.9 Ixekizumab Q2W 1
436 21.7 Ixekizumab Q2W 1
437 35.2 Ixekizumab Q2W 1
438 25.0 Ixekizumab Q2W 1
439 25.4 Ixekizumab Q2W 1
440 24.8 Ixekizumab Q2W 1
441 35.4 Ixekizumab Q2W 1
442 47.9 Ixekizumab Q2W 1
443 23.0 Ixekizumab Q2W 1
444 32.0 Ixekizumab Q2W 1
445 60.2 Ixekizumab Q2W 1
446 21.1 Ixekizumab Q2W 1
447 49.0 Ixekizumab Q2W 1
448 34.1 Ixekizumab Q2W 1
449 27.4 Ixekizumab Q2W 1
450 27.7 Ixekizumab Q2W 1
451 23.1 Ixekizumab Q2W 1
452 44.1 Ixekizumab Q2W 1
453 28.9 Ixekizumab Q2W 1
454 29.6 Ixekizumab Q2W 1
455 24.0 Ixekizumab Q2W 1
456 33.3 Ixekizumab Q2W 1
457 27.2 Ixekizumab Q2W 1
458 27.1 Ixekizumab Q2W 1
459 31.9 Ixekizumab Q2W 1
460 33.7 Ixekizumab Q2W 1
461 38.7 Ixekizumab Q2W 1
462 23.2 Ixekizumab Q2W 1
463 31.4 Ixekizumab Q2W 1
464 26.9 Ixekizumab Q2W 1
465 23.5 Ixekizumab Q2W 1
466 32.7 Ixekizumab Q2W 1
467 27.5 Ixekizumab Q2W 1
468 32.8 Ixekizumab Q2W 1
469 23.2 Ixekizumab Q2W 1
470 30.1 Ixekizumab Q2W 1
471 26.6 Ixekizumab Q2W 1
472 28.9 Ixekizumab Q2W 1
473 23.4 Ixekizumab Q2W 1
474 28.4 Ixekizumab Q2W 1
475 28.7 Ixekizumab Q2W 1
476 21.1 Ixekizumab Q2W 1
477 25.2 Ixekizumab Q2W 1
478 32.0 Ixekizumab Q2W 1
479 24.0 Ixekizumab Q2W 1
480 32.4 Ixekizumab Q2W 1
481 38.9 Ixekizumab Q2W 1
482 24.2 Ixekizumab Q2W 1
483 32.4 Ixekizumab Q2W 1
484 27.9 Ixekizumab Q2W 1
485 28.7 Ixekizumab Q2W 1
486 32.4 Ixekizumab Q2W 1
487 22.1 Ixekizumab Q2W 1
488 32.3 Ixekizumab Q2W 1
489 32.7 Ixekizumab Q2W 1
490 27.6 Ixekizumab Q2W 1
491 25.0 Ixekizumab Q2W 1
492 23.1 Ixekizumab Q2W 1
493 27.9 Ixekizumab Q2W 1
494 29.8 Ixekizumab Q2W 1
495 21.1 Ixekizumab Q2W 1
496 35.4 Ixekizumab Q2W 1
497 23.7 Ixekizumab Q2W 1
498 25.5 Ixekizumab Q2W 1
499 26.6 Ixekizumab Q2W 1
500 42.7 Ixekizumab Q2W 1
501 53.4 Ixekizumab Q2W 1
502 34.9 Ixekizumab Q2W 1
503 29.6 Ixekizumab Q2W 1
504 23.5 Ixekizumab Q2W 1
505 30.7 Ixekizumab Q2W 1
506 44.3 Ixekizumab Q2W 1
507 29.6 Ixekizumab Q2W 1
508 22.6 Ixekizumab Q2W 1
509 32.3 Ixekizumab Q2W 1
510 21.1 Ixekizumab Q2W 1
511 27.7 Ixekizumab Q2W 1
512 32.5 Ixekizumab Q2W 1
513 32.4 Ixekizumab Q2W 1
514 18.3 Ixekizumab Q2W 1
515 26.3 Ixekizumab Q2W 1
516 27.6 Ixekizumab Q2W 1
517 31.4 Ixekizumab Q2W 1
518 27.8 Ixekizumab Q2W 1
519 37.6 Ixekizumab Q2W 1
520 33.3 Ixekizumab Q2W 1
521 26.4 Ixekizumab Q2W 1
522 22.5 Ixekizumab Q2W 1
523 32.8 Ixekizumab Q2W 1
524 30.7 Ixekizumab Q2W 1
525 23.8 Ixekizumab Q2W 1
526 29.4 Ixekizumab Q2W 1
527 27.5 Ixekizumab Q2W 1
528 26.6 Ixekizumab Q2W 1
529 26.8 Ixekizumab Q2W 1
530 28.8 Ixekizumab Q2W 1
531 31.3 Ixekizumab Q2W 1
532 29.8 Ixekizumab Q2W 1
533 19.9 Ixekizumab Q2W 1
534 38.4 Ixekizumab Q2W 1
535 22.1 Ixekizumab Q2W 1
536 44.3 Ixekizumab Q2W 1
537 19.9 Ixekizumab Q2W 1
538 38.7 Ixekizumab Q2W 1
539 29.2 Ixekizumab Q2W 1
540 23.4 Ixekizumab Q2W 1
541 27.2 Ixekizumab Q2W 1
542 29.0 Ixekizumab Q2W 1
543 28.2 Ixekizumab Q2W 1
544 25.5 Ixekizumab Q2W 1
545 48.9 Ixekizumab Q2W 1
546 25.2 Ixekizumab Q2W 1
547 40.0 Ixekizumab Q2W 1
548 32.7 Ixekizumab Q2W 1
549 26.0 Ixekizumab Q2W 1
550 31.4 Ixekizumab Q2W 1
551 40.7 Ixekizumab Q2W 1
552 25.5 Ixekizumab Q2W 1
553 29.7 Ixekizumab Q2W 1
554 29.4 Ixekizumab Q2W 1
555 26.1 Ixekizumab Q2W 1
556 25.1 Ixekizumab Q2W 1
557 38.9 Ixekizumab Q2W 1
558 37.6 Ixekizumab Q2W 1
559 36.0 Ixekizumab Q2W 1
560 30.1 Ixekizumab Q2W 1
561 29.6 Ixekizumab Q2W 1
562 37.6 Ixekizumab Q2W 1
563 26.2 Ixekizumab Q2W 1
564 30.1 Ixekizumab Q2W 1
565 30.4 Ixekizumab Q2W 1
566 29.0 Ixekizumab Q2W 1
567 24.8 Ixekizumab Q2W 1
568 35.4 Ixekizumab Q2W 1
569 21.2 Ixekizumab Q2W 1
570 26.8 Ixekizumab Q2W 1
571 33.3 Ixekizumab Q2W 1
572 43.0 Ixekizumab Q2W 1
573 23.0 Ixekizumab Q2W 1
574 29.4 Ixekizumab Q2W 1
575 27.7 Ixekizumab Q2W 1
576 28.7 Ixekizumab Q2W 1
577 22.5 Ixekizumab Q2W 1
578 25.6 Ixekizumab Q2W 1
579 26.8 Ixekizumab Q2W 1
580 27.8 Ixekizumab Q2W 1
581 25.8 Ixekizumab Q2W 1
582 26.6 Ixekizumab Q2W 1
583 25.5 Ixekizumab Q2W 1
584 31.9 Ixekizumab Q2W 1
585 27.3 Ixekizumab Q2W 1
586 23.3 Ixekizumab Q2W 1
587 30.1 Ixekizumab Q2W 1
588 26.1 Ixekizumab Q2W 1
589 32.2 Ixekizumab Q2W 1
590 31.1 Ixekizumab Q2W 1
591 22.5 Ixekizumab Q2W 1
592 38.5 Ixekizumab Q2W 1
593 19.8 Ixekizumab Q2W 1
594 30.0 Ixekizumab Q2W 1
595 27.6 Ixekizumab Q2W 1
596 23.2 Ixekizumab Q2W 1
597 32.7 Ixekizumab Q2W 1
598 21.1 Ixekizumab Q2W 1
599 33.2 Ixekizumab Q2W 1
600 23.5 Ixekizumab Q2W 1
601 24.8 Ixekizumab Q2W 1
602 29.8 Ixekizumab Q2W 1
603 28.3 Ixekizumab Q2W 1
604 36.0 Ixekizumab Q2W 1
605 47.6 Ixekizumab Q2W 1
606 33.0 Ixekizumab Q2W 1
607 22.5 Ixekizumab Q2W 1
608 36.0 Ixekizumab Q2W 1
609 33.0 Ixekizumab Q2W 1
610 35.6 Ixekizumab Q2W 1
611 26.6 Ixekizumab Q2W 1
612 30.4 Ixekizumab Q2W 1
613 22.9 Ixekizumab Q2W 1
614 26.0 Ixekizumab Q2W 1
615 37.6 Ixekizumab Q2W 1
616 24.8 Ixekizumab Q2W 1
617 52.7 Ixekizumab Q2W 1
618 26.2 Ixekizumab Q2W 1
619 25.6 Ixekizumab Q2W 1
620 24.8 Ixekizumab Q2W 1
621 38.7 Ixekizumab Q2W 1
622 42.7 Ixekizumab Q2W 1
623 25.7 Ixekizumab Q2W 1
624 26.3 Ixekizumab Q2W 1
625 37.6 Ixekizumab Q2W 1
626 20.7 Ixekizumab Q2W 1
627 33.8 Ixekizumab Q2W 1
628 27.4 Ixekizumab Q2W 1
629 31.9 Ixekizumab Q2W 1
630 25.5 Ixekizumab Q2W 1
631 30.4 Ixekizumab Q2W 1
632 44.7 Ixekizumab Q2W 1
633 26.6 Ixekizumab Q2W 1
634 22.9 Ixekizumab Q2W 1
635 25.5 Ixekizumab Q2W 1
636 25.5 Ixekizumab Q2W 1
637 27.8 Ixekizumab Q2W 1
638 26.2 Ixekizumab Q2W 1
639 23.0 Ixekizumab Q2W 1
640 44.1 Ixekizumab Q2W 1
641 27.9 Ixekizumab Q2W 1
642 31.1 Ixekizumab Q2W 1
643 20.1 Ixekizumab Q2W 1
644 23.4 Ixekizumab Q2W 1
645 33.2 Ixekizumab Q2W 1
646 27.4 Ixekizumab Q2W 1
647 27.5 Ixekizumab Q2W 1
648 32.4 Ixekizumab Q2W 1
649 26.9 Ixekizumab Q2W 1
650 32.8 Ixekizumab Q2W 1
651 27.8 Ixekizumab Q2W 1
652 44.7 Ixekizumab Q2W 1
653 22.5 Ixekizumab Q2W 1
654 47.6 Ixekizumab Q2W 1
655 36.0 Ixekizumab Q2W 1
656 27.1 Ixekizumab Q2W 1
657 31.2 Ixekizumab Q2W 1
658 27.4 Ixekizumab Q2W 1
659 26.1 Ixekizumab Q2W 1
660 34.1 Ixekizumab Q2W 1
661 19.4 Ixekizumab Q2W 1
662 36.3 Ixekizumab Q2W 1
663 36.0 Ixekizumab Q2W 1
664 28.1 Ixekizumab Q2W 1
665 38.7 Ixekizumab Q2W 1
666 38.9 Ixekizumab Q2W 1
667 25.5 Ixekizumab Q2W 1
668 22.2 Ixekizumab Q2W 1
669 19.9 Ixekizumab Q2W 1
670 32.2 Ixekizumab Q2W 1
671 49.0 Ixekizumab Q2W 1
672 31.1 Ixekizumab Q2W 1
673 23.5 Ixekizumab Q2W 1
674 44.0 Ixekizumab Q2W 1
675 29.8 Ixekizumab Q2W 1
676 32.0 Ixekizumab Q2W 1
677 52.7 Ixekizumab Q2W 1
678 32.8 Ixekizumab Q2W 1
679 32.7 Ixekizumab Q2W 1
680 35.5 Ixekizumab Q2W 1
681 32.1 Ixekizumab Q2W 1
682 24.4 Ixekizumab Q2W 1
683 27.6 Ixekizumab Q2W 1
684 23.8 Ixekizumab Q2W 1
685 32.6 Ixekizumab Q2W 1
686 32.0 Ixekizumab Q2W 1
687 36.4 Ixekizumab Q2W 1
688 21.7 Ixekizumab Q2W 1
689 22.5 Ixekizumab Q2W 1
690 39.3 Ixekizumab Q2W 1
691 26.8 Ixekizumab Q2W 1
692 24.8 Ixekizumab Q2W 1
693 29.6 Ixekizumab Q2W 1
694 53.4 Ixekizumab Q2W 1
695 28.3 Ixekizumab Q2W 1
696 25.3 Ixekizumab Q2W 1
697 32.1 Ixekizumab Q2W 1
698 36.8 Ixekizumab Q2W 1
699 25.4 Ixekizumab Q2W 1
700 30.7 Ixekizumab Q2W 1
701 21.1 Ixekizumab Q2W 1
702 29.6 Ixekizumab Q2W 1
703 26.0 Ixekizumab Q2W 1
704 31.2 Ixekizumab Q2W 1
705 19.9 Ixekizumab Q2W 1
706 31.7 Ixekizumab Q2W 1
707 32.1 Ixekizumab Q2W 1
708 37.3 Ixekizumab Q4W 1
709 28.6 Ixekizumab Q4W 1
710 27.9 Ixekizumab Q4W 1
711 48.2 Ixekizumab Q4W 1
712 42.0 Ixekizumab Q4W 1
713 30.3 Ixekizumab Q4W 1
714 22.0 Ixekizumab Q4W 1
715 34.8 Ixekizumab Q4W 1
716 35.0 Ixekizumab Q4W 1
717 24.4 Ixekizumab Q4W 1
718 28.4 Ixekizumab Q4W 1
719 29.0 Ixekizumab Q4W 1
720 NaN Ixekizumab Q4W 1
721 22.4 Ixekizumab Q4W 1
722 29.3 Ixekizumab Q4W 1
723 27.7 Ixekizumab Q4W 1
724 43.9 Ixekizumab Q4W 1
725 43.4 Ixekizumab Q4W 1
726 24.2 Ixekizumab Q4W 1
727 43.4 Ixekizumab Q4W 1
728 26.0 Ixekizumab Q4W 1
729 24.8 Ixekizumab Q4W 1
730 29.6 Ixekizumab Q4W 1
731 37.0 Ixekizumab Q4W 1
732 29.3 Ixekizumab Q4W 1
733 28.6 Ixekizumab Q4W 1
734 26.6 Ixekizumab Q4W 1
735 24.6 Ixekizumab Q4W 1
736 21.0 Ixekizumab Q4W 1
737 20.6 Ixekizumab Q4W 1
738 32.0 Ixekizumab Q4W 1
739 40.4 Ixekizumab Q4W 1
740 35.9 Ixekizumab Q4W 1
741 40.9 Ixekizumab Q4W 1
742 31.2 Ixekizumab Q4W 1
743 26.9 Ixekizumab Q4W 1
744 22.7 Ixekizumab Q4W 1
745 31.9 Ixekizumab Q4W 1
746 53.8 Ixekizumab Q4W 1
747 20.6 Ixekizumab Q4W 1
748 23.9 Ixekizumab Q4W 1
749 34.4 Ixekizumab Q4W 1
750 27.2 Ixekizumab Q4W 1
751 38.4 Ixekizumab Q4W 1
752 37.2 Ixekizumab Q4W 1
753 34.2 Ixekizumab Q4W 1
754 32.5 Ixekizumab Q4W 1
755 31.8 Ixekizumab Q4W 1
756 38.4 Ixekizumab Q4W 1
757 32.0 Ixekizumab Q4W 1
758 31.6 Ixekizumab Q4W 1
759 29.3 Ixekizumab Q4W 1
760 29.0 Ixekizumab Q4W 1
761 21.4 Ixekizumab Q4W 1
762 37.9 Ixekizumab Q4W 1
763 29.3 Ixekizumab Q4W 1
764 33.8 Ixekizumab Q4W 1
765 38.5 Ixekizumab Q4W 1
766 23.0 Ixekizumab Q4W 1
767 38.8 Ixekizumab Q4W 1
768 28.8 Ixekizumab Q4W 1
769 23.3 Ixekizumab Q4W 1
770 30.0 Ixekizumab Q4W 1
771 31.6 Ixekizumab Q4W 1
772 24.6 Ixekizumab Q4W 1
773 29.7 Ixekizumab Q4W 1
774 30.7 Ixekizumab Q4W 1
775 37.9 Ixekizumab Q4W 1
776 29.9 Ixekizumab Q4W 1
777 23.2 Ixekizumab Q4W 1
778 25.9 Ixekizumab Q4W 1
779 31.0 Ixekizumab Q4W 1
780 34.2 Ixekizumab Q4W 1
781 24.2 Ixekizumab Q4W 1
782 26.8 Ixekizumab Q4W 1
783 37.3 Ixekizumab Q4W 1
784 31.6 Ixekizumab Q4W 1
785 30.6 Ixekizumab Q4W 1
786 34.8 Ixekizumab Q4W 1
787 43.4 Ixekizumab Q4W 1
788 23.0 Ixekizumab Q4W 1
789 25.8 Ixekizumab Q4W 1
790 32.3 Ixekizumab Q4W 1
791 27.5 Ixekizumab Q4W 1
792 30.5 Ixekizumab Q4W 1
793 40.6 Ixekizumab Q4W 1
794 29.4 Ixekizumab Q4W 1
795 32.0 Ixekizumab Q4W 1
796 42.6 Ixekizumab Q4W 1
797 26.6 Ixekizumab Q4W 1
798 47.6 Ixekizumab Q4W 1
799 27.9 Ixekizumab Q4W 1
800 24.8 Ixekizumab Q4W 1
801 23.6 Ixekizumab Q4W 1
802 29.3 Ixekizumab Q4W 1
803 26.0 Ixekizumab Q4W 1
804 50.5 Ixekizumab Q4W 1
805 31.9 Ixekizumab Q4W 1
806 26.5 Ixekizumab Q4W 1
807 33.3 Ixekizumab Q4W 1
808 34.6 Ixekizumab Q4W 1
809 24.8 Ixekizumab Q4W 1
810 24.9 Ixekizumab Q4W 1
811 27.7 Ixekizumab Q4W 1
812 23.8 Ixekizumab Q4W 1
813 33.5 Ixekizumab Q4W 1
814 25.4 Ixekizumab Q4W 1
815 33.1 Ixekizumab Q4W 1
816 31.2 Ixekizumab Q4W 1
817 26.0 Ixekizumab Q4W 1
818 33.3 Ixekizumab Q4W 1
819 34.0 Ixekizumab Q4W 1
820 42.6 Ixekizumab Q4W 1
821 38.4 Ixekizumab Q4W 1
822 28.4 Ixekizumab Q4W 1
823 26.7 Ixekizumab Q4W 1
824 33.3 Ixekizumab Q4W 1
825 23.5 Ixekizumab Q4W 1
826 32.0 Ixekizumab Q4W 1
827 34.6 Ixekizumab Q4W 1
828 38.4 Ixekizumab Q4W 1
829 34.3 Ixekizumab Q4W 1
830 24.6 Ixekizumab Q4W 1
831 25.4 Ixekizumab Q4W 1
832 34.2 Ixekizumab Q4W 1
833 33.6 Ixekizumab Q4W 1
834 30.1 Ixekizumab Q4W 1
835 32.0 Ixekizumab Q4W 1
836 25.6 Ixekizumab Q4W 1
837 42.6 Ixekizumab Q4W 1
838 26.3 Ixekizumab Q4W 1
839 26.9 Ixekizumab Q4W 1
840 30.6 Ixekizumab Q4W 1
841 27.4 Ixekizumab Q4W 1
842 23.5 Ixekizumab Q4W 1
843 38.8 Ixekizumab Q4W 1
844 31.6 Ixekizumab Q4W 1
845 27.8 Ixekizumab Q4W 1
846 31.8 Ixekizumab Q4W 1
847 30.3 Ixekizumab Q4W 1
848 22.0 Ixekizumab Q4W 1
849 42.3 Ixekizumab Q4W 1
850 29.3 Ixekizumab Q4W 1
851 35.4 Ixekizumab Q4W 1
852 32.7 Ixekizumab Q4W 1
853 43.7 Ixekizumab Q4W 1
854 43.9 Ixekizumab Q4W 1
855 31.4 Ixekizumab Q4W 1
856 32.7 Ixekizumab Q4W 1
857 22.8 Ixekizumab Q4W 1
858 25.6 Ixekizumab Q4W 1
859 29.2 Ixekizumab Q4W 1
860 29.3 Ixekizumab Q4W 1
861 32.0 Ixekizumab Q4W 1
862 29.9 Ixekizumab Q4W 1
863 34.3 Ixekizumab Q4W 1
864 29.7 Ixekizumab Q4W 1
865 34.6 Ixekizumab Q4W 1
866 38.4 Ixekizumab Q4W 1
867 29.8 Ixekizumab Q4W 1
868 43.4 Ixekizumab Q4W 1
869 31.8 Ixekizumab Q4W 1
870 40.8 Ixekizumab Q4W 1
871 30.1 Ixekizumab Q4W 1
872 34.7 Ixekizumab Q4W 1
873 43.9 Ixekizumab Q4W 1
874 34.2 Ixekizumab Q4W 1
875 34.4 Ixekizumab Q4W 1
876 32.5 Ixekizumab Q4W 1
877 31.9 Ixekizumab Q4W 1
878 32.0 Ixekizumab Q4W 1
879 29.7 Ixekizumab Q4W 1
880 26.0 Ixekizumab Q4W 1
881 29.4 Ixekizumab Q4W 1
882 43.6 Ixekizumab Q4W 1
883 26.2 Ixekizumab Q4W 1
884 35.7 Ixekizumab Q4W 1
885 24.4 Ixekizumab Q4W 1
886 26.0 Ixekizumab Q4W 1
887 46.8 Ixekizumab Q4W 1
888 35.0 Ixekizumab Q4W 1
889 29.7 Ixekizumab Q4W 1
890 32.7 Ixekizumab Q4W 1
891 40.6 Ixekizumab Q4W 1
892 40.9 Ixekizumab Q4W 1
893 31.2 Ixekizumab Q4W 1
894 32.5 Ixekizumab Q4W 1
895 23.0 Ixekizumab Q4W 1
896 29.6 Ixekizumab Q4W 1
897 32.9 Ixekizumab Q4W 1
898 27.8 Ixekizumab Q4W 1
899 30.0 Ixekizumab Q4W 1
900 34.7 Ixekizumab Q4W 1
901 36.9 Ixekizumab Q4W 1
902 31.6 Ixekizumab Q4W 1
903 40.9 Ixekizumab Q4W 1
904 24.5 Ixekizumab Q4W 1
905 25.1 Ixekizumab Q4W 1
906 34.2 Ixekizumab Q4W 1
907 29.9 Ixekizumab Q4W 1
908 27.8 Ixekizumab Q4W 1
909 20.8 Ixekizumab Q4W 1
910 29.2 Ixekizumab Q4W 1
911 23.4 Ixekizumab Q4W 1
912 29.4 Ixekizumab Q4W 1
913 26.6 Ixekizumab Q4W 1
914 33.3 Ixekizumab Q4W 1
915 33.1 Ixekizumab Q4W 1
916 33.1 Ixekizumab Q4W 1
917 27.2 Ixekizumab Q4W 1
918 24.1 Ixekizumab Q4W 1
919 33.1 Ixekizumab Q4W 1
920 35.7 Ixekizumab Q4W 1
921 29.7 Ixekizumab Q4W 1
922 23.2 Ixekizumab Q4W 1
923 23.0 Ixekizumab Q4W 1
924 25.9 Ixekizumab Q4W 1
925 26.6 Ixekizumab Q4W 1
926 32.7 Ixekizumab Q4W 1
927 27.5 Ixekizumab Q4W 1
928 NaN Ixekizumab Q4W 1
929 32.4 Ixekizumab Q4W 1
930 26.2 Ixekizumab Q4W 1
931 42.7 Ixekizumab Q4W 1
932 25.7 Ixekizumab Q4W 1
933 34.3 Ixekizumab Q4W 1
934 26.9 Ixekizumab Q4W 1
935 34.0 Ixekizumab Q4W 1
936 35.1 Ixekizumab Q4W 1
937 26.0 Ixekizumab Q4W 1
938 33.1 Ixekizumab Q4W 1
939 32.0 Ixekizumab Q4W 1
940 32.5 Ixekizumab Q4W 1
941 26.9 Ixekizumab Q4W 1
942 44.3 Ixekizumab Q4W 1
943 26.0 Ixekizumab Q4W 1
944 34.7 Ixekizumab Q4W 1
945 21.6 Ixekizumab Q4W 1
946 30.9 Ixekizumab Q4W 1
947 20.8 Ixekizumab Q4W 1
948 29.0 Ixekizumab Q4W 1
949 25.2 Ixekizumab Q4W 1
950 25.5 Ixekizumab Q4W 1
951 27.8 Ixekizumab Q4W 1
952 31.2 Ixekizumab Q4W 1
953 29.7 Ixekizumab Q4W 1
954 33.1 Ixekizumab Q4W 1
955 28.4 Ixekizumab Q4W 1
956 23.3 Ixekizumab Q4W 1
957 31.1 Ixekizumab Q4W 1
958 29.6 Ixekizumab Q4W 1
959 26.6 Ixekizumab Q4W 1
960 25.4 Ixekizumab Q4W 1
961 27.8 Ixekizumab Q4W 1
962 35.1 Ixekizumab Q4W 1
963 33.6 Ixekizumab Q4W 1
964 43.7 Ixekizumab Q4W 1
965 34.3 Ixekizumab Q4W 1
966 29.0 Ixekizumab Q4W 1
967 25.2 Ixekizumab Q4W 1
968 29.0 Ixekizumab Q4W 1
969 25.8 Ixekizumab Q4W 1
970 21.6 Ixekizumab Q4W 1
971 23.5 Ixekizumab Q4W 1
972 26.4 Ixekizumab Q4W 1
973 21.6 Ixekizumab Q4W 1
974 30.6 Ixekizumab Q4W 1
975 28.4 Ixekizumab Q4W 1
976 24.0 Ixekizumab Q4W 1
977 30.3 Ixekizumab Q4W 1
978 22.3 Ixekizumab Q4W 1
979 33.1 Ixekizumab Q4W 1
980 43.4 Ixekizumab Q4W 1
981 30.0 Ixekizumab Q4W 1
982 21.4 Ixekizumab Q4W 1
983 24.7 Ixekizumab Q4W 1
984 34.2 Ixekizumab Q4W 1
985 32.2 Ixekizumab Q4W 1
986 31.4 Ixekizumab Q4W 1
987 26.6 Ixekizumab Q4W 1
988 25.5 Ixekizumab Q4W 1
989 24.2 Ixekizumab Q4W 1
990 27.7 Ixekizumab Q4W 1
991 27.4 Ixekizumab Q4W 1
992 37.2 Ixekizumab Q4W 1
993 28.8 Ixekizumab Q4W 1
994 29.3 Ixekizumab Q4W 1
995 38.4 Ixekizumab Q4W 1
996 21.5 Ixekizumab Q4W 1
997 29.4 Ixekizumab Q4W 1
998 27.8 Ixekizumab Q4W 1
999 28.8 Ixekizumab Q4W 1
1000 26.9 Ixekizumab Q4W 1
1001 28.8 Ixekizumab Q4W 1
1002 30.3 Ixekizumab Q4W 1
1003 26.4 Ixekizumab Q4W 1
1004 48.2 Ixekizumab Q4W 1
1005 35.2 Ixekizumab Q4W 1
1006 32.0 Ixekizumab Q4W 1
1007 30.0 Ixekizumab Q4W 1
1008 24.5 Ixekizumab Q4W 1
1009 36.1 Ixekizumab Q4W 1
1010 35.9 Ixekizumab Q4W 1
1011 24.8 Ixekizumab Q4W 1
1012 35.8 Ixekizumab Q4W 1
1013 37.3 Ixekizumab Q4W 1
1014 33.4 Ixekizumab Q4W 1
1015 38.1 Ixekizumab Q4W 1
1016 27.7 Ixekizumab Q4W 1
1017 31.0 Ixekizumab Q4W 1
1018 44.8 Ixekizumab Q4W 1
1019 28.9 Ixekizumab Q4W 1
1020 31.4 Ixekizumab Q4W 1
1021 29.0 Ixekizumab Q4W 1
1022 28.4 Ixekizumab Q4W 1
1023 40.6 Ixekizumab Q4W 1
1024 22.4 Ixekizumab Q4W 1
1025 22.5 Ixekizumab Q4W 1
1026 34.8 Ixekizumab Q4W 1
1027 26.7 Ixekizumab Q4W 1
1028 32.0 Ixekizumab Q4W 1
1029 40.6 Ixekizumab Q4W 1
1030 NaN Ixekizumab Q4W 1
1031 32.0 Ixekizumab Q4W 1
1032 22.5 Ixekizumab Q4W 1
1033 29.4 Ixekizumab Q4W 1
1034 22.8 Ixekizumab Q4W 1
1035 32.8 Ixekizumab Q4W 1
1036 25.1 Ixekizumab Q4W 1
1037 26.9 Ixekizumab Q4W 1
1038 26.7 Ixekizumab Q4W 1
1039 32.5 Ixekizumab Q4W 1
1040 26.0 Ixekizumab Q4W 1
1041 30.0 Ixekizumab Q4W 1
1042 33.8 Ixekizumab Q4W 1
1043 27.5 Ixekizumab Q4W 1
1044 45.1 Ixekizumab Q4W 1
1045 25.7 Ixekizumab Q4W 1
1046 35.5 Ixekizumab Q4W 1
1047 43.4 Ixekizumab Q4W 1
1048 31.2 Ixekizumab Q4W 1
1049 27.8 Ixekizumab Q4W 1
1050 42.0 Ixekizumab Q4W 1
1051 29.2 Ixekizumab Q4W 1
1052 37.3 Ixekizumab Q4W 1
1053 26.9 Ixekizumab Q4W 1
1054 22.6 Ixekizumab Q4W 1
1055 30.0 Placebo 1
1056 38.7 Placebo 1
1057 32.7 Placebo 1
1058 30.8 Placebo 1
1059 33.6 Placebo 1
1060 28.6 Placebo 1
1061 34.0 Placebo 1
1062 35.1 Placebo 1
1063 19.5 Placebo 1
1064 26.0 Placebo 1
1065 21.3 Placebo 1
1066 19.4 Placebo 1
1067 28.6 Placebo 1
1068 34.4 Placebo 1
1069 22.7 Placebo 1
1070 34.8 Placebo 1
1071 39.9 Placebo 1
1072 25.2 Placebo 1
1073 29.2 Placebo 1
1074 33.6 Placebo 1
1075 26.0 Placebo 1
1076 31.8 Placebo 1
1077 35.1 Placebo 1
1078 26.0 Placebo 1
1079 20.8 Placebo 1
1080 21.5 Placebo 1
1081 30.0 Placebo 1
1082 30.2 Placebo 1
1083 30.3 Placebo 1
1084 25.7 Placebo 1
1085 26.0 Placebo 1
1086 30.2 Placebo 1
1087 38.3 Placebo 1
1088 33.0 Placebo 1
1089 38.2 Placebo 1
1090 30.6 Placebo 1
1091 60.6 Placebo 1
1092 32.4 Placebo 1
1093 35.8 Placebo 1
1094 28.1 Placebo 1
1095 33.9 Placebo 1
1096 30.6 Placebo 1
1097 32.9 Placebo 1
1098 39.9 Placebo 1
1099 29.9 Placebo 1
1100 37.3 Placebo 1
1101 21.6 Placebo 1
1102 NaN Placebo 1
1103 28.9 Placebo 1
1104 24.3 Placebo 1
1105 21.6 Placebo 1
1106 30.5 Placebo 1
1107 31.2 Placebo 1
1108 27.0 Placebo 1
1109 22.7 Placebo 1
1110 21.5 Placebo 1
1111 36.1 Placebo 1
1112 25.7 Placebo 1
1113 36.9 Placebo 1
1114 44.1 Placebo 1
1115 25.7 Placebo 1
1116 25.9 Placebo 1
1117 36.2 Placebo 1
1118 25.1 Placebo 1
1119 38.3 Placebo 1
1120 32.9 Placebo 1
1121 25.7 Placebo 1
1122 26.5 Placebo 1
1123 21.9 Placebo 1
1124 34.8 Placebo 1
1125 28.3 Placebo 1
1126 19.5 Placebo 1
1127 28.7 Placebo 1
1128 25.7 Placebo 1
1129 31.2 Placebo 1
1130 32.5 Placebo 1
1131 36.2 Placebo 1
1132 32.7 Placebo 1
1133 21.2 Placebo 1
1134 27.8 Placebo 1
1135 34.8 Placebo 1
1136 29.3 Placebo 1
1137 18.8 Placebo 1
1138 27.8 Placebo 1
1139 33.9 Placebo 1
1140 32.0 Placebo 1
1141 34.9 Placebo 1
1142 39.3 Placebo 1
1143 29.0 Placebo 1
1144 29.2 Placebo 1
1145 26.0 Placebo 1
1146 28.7 Placebo 1
1147 24.2 Placebo 1
1148 36.3 Placebo 1
1149 33.7 Placebo 1
1150 33.6 Placebo 1
1151 25.8 Placebo 1
1152 39.0 Placebo 1
1153 28.6 Placebo 1
1154 26.4 Placebo 1
1155 38.6 Placebo 1
1156 30.2 Placebo 1
1157 18.3 Placebo 1
1158 29.2 Placebo 1
1159 43.1 Placebo 1
1160 26.5 Placebo 1
1161 25.5 Placebo 1
1162 31.8 Placebo 1
1163 22.4 Placebo 1
1164 21.6 Placebo 1
1165 30.6 Placebo 1
1166 27.0 Placebo 1
1167 34.5 Placebo 1
1168 38.7 Placebo 1
1169 27.0 Placebo 1
1170 30.6 Placebo 1
1171 30.6 Placebo 1
1172 25.2 Placebo 1
1173 27.9 Placebo 1
1174 33.8 Placebo 1
1175 34.0 Placebo 1
1176 32.9 Placebo 1
1177 22.8 Placebo 1
1178 36.1 Placebo 1
1179 37.2 Placebo 1
1180 19.5 Placebo 1
1181 24.2 Placebo 1
1182 22.7 Placebo 1
1183 60.6 Placebo 1
1184 21.6 Placebo 1
1185 35.8 Placebo 1
1186 39.3 Placebo 1
1187 29.6 Placebo 1
1188 25.1 Placebo 1
1189 28.0 Placebo 1
1190 37.3 Placebo 1
1191 34.9 Placebo 1
1192 35.8 Placebo 1
1193 30.7 Placebo 1
1194 34.4 Placebo 1
1195 35.1 Placebo 1
1196 22.5 Placebo 1
1197 28.7 Placebo 1
1198 26.2 Placebo 1
1199 44.1 Placebo 1
1200 20.8 Placebo 1
1201 27.0 Placebo 1
1202 24.5 Placebo 1
1203 25.8 Placebo 1
1204 32.7 Placebo 1
1205 26.0 Placebo 1
1206 37.6 Placebo 1
1207 29.3 Placebo 1
1208 25.7 Placebo 1
1209 51.3 Placebo 1
1210 19.4 Placebo 1
1211 37.6 Placebo 1
1212 31.8 Placebo 1
1213 38.2 Placebo 1
1214 25.5 Placebo 1
1215 19.5 Placebo 1
1216 25.1 Placebo 1
1217 40.7 Placebo 1
1218 60.6 Placebo 1
1219 32.3 Placebo 1
1220 21.3 Placebo 1
1221 27.8 Placebo 1
## Rows: 1,221
## Columns: 7
## Groups: X, bmi [1,221]
## $ X        <int> 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,…
## $ trial    <chr> "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", "UNCOVER-2", …
## $ trt      <chr> "Etanercept", "Etanercept", "Etanercept", "Etanercept", "Etanercept", "Etanercept", "Etanercept", "Etanercept", "Etanercept", "Eta…
## $ age      <int> 51, 64, 59, 54, 50, 57, 36, 54, 50, 26, 61, 29, 52, 42, 58, 47, 37, 49, 41, 51, 25, 45, 49, 57, 43, 59, 45, 36, 56, 47, 43, 76, 51…
## $ bmi      <dbl> 34.5, 24.2, 26.1, 19.7, 30.3, 25.8, 30.3, 38.1, 30.3, 27.2, 31.5, 23.4, 27.5, 22.7, 34.6, 22.6, 41.9, 45.2, 28.1, 30.2, 25.1, 28.9…
## $ male     <lgl> TRUE, TRUE, TRUE, TRUE, TRUE, TRUE, TRUE, FALSE, FALSE, TRUE, TRUE, FALSE, FALSE, FALSE, TRUE, TRUE, FALSE, FALSE, TRUE, TRUE, FAL…
## $ response <int> 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 0, 1, 1, 0, 1, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1, 1, 1, 0, 1…
##           X       trial         trt         age         bmi        male    response 
##   "integer" "character" "character"   "integer"   "numeric"   "logical"   "integer"
## # A tibble: 1 x 2
##   trial       avg
##   <chr>     <dbl>
## 1 UNCOVER-2  46.1
## # A tibble: 4 x 2
##   trt              avg
##   <chr>          <dbl>
## 1 Placebo         45.2
## 2 Ixekizumab Q2W  45.5
## 3 Ixekizumab Q4W  45.6
## 4 Etanercept      47.5
## # A tibble: 1,221 x 7
## # Groups:   X, bmi [1,221]
##        X trial     trt              age   bmi male  response
##    <int> <chr>     <chr>          <int> <dbl> <lgl>    <int>
##  1   374 UNCOVER-2 Ixekizumab Q2W    18  25.3 TRUE         0
##  2   379 UNCOVER-2 Ixekizumab Q2W    18  26.1 TRUE         1
##  3   487 UNCOVER-2 Ixekizumab Q2W    18  22.1 TRUE         1
##  4   569 UNCOVER-2 Ixekizumab Q2W    18  21.2 FALSE        0
##  5   659 UNCOVER-2 Ixekizumab Q2W    18  26.1 TRUE         1
##  6   857 UNCOVER-2 Ixekizumab Q4W    18  22.8 FALSE        0
##  7    61 UNCOVER-2 Etanercept        19  41.4 TRUE         0
##  8   325 UNCOVER-2 Etanercept        19  29.3 TRUE         1
##  9   413 UNCOVER-2 Ixekizumab Q2W    19  21.2 FALSE        1
## 10   696 UNCOVER-2 Ixekizumab Q2W    19  25.3 TRUE         1
## # … with 1,211 more rows
## # A tibble: 12 x 7
## # Groups:   X, bmi [12]
##        X trial     trt              age   bmi male  response
##    <int> <chr>     <chr>          <int> <dbl> <lgl>    <int>
##  1    47 UNCOVER-2 Etanercept        78  24.2 TRUE         0
##  2   187 UNCOVER-2 Etanercept        71  28.7 FALSE        1
##  3   366 UNCOVER-2 Ixekizumab Q2W    77  23.3 FALSE        1
##  4   414 UNCOVER-2 Ixekizumab Q2W    77  28.4 TRUE         1
##  5   418 UNCOVER-2 Ixekizumab Q2W    84  26.8 TRUE         1
##  6   430 UNCOVER-2 Ixekizumab Q2W    84  27.7 FALSE        1
##  7   484 UNCOVER-2 Ixekizumab Q2W    75  27.9 FALSE        1
##  8   586 UNCOVER-2 Ixekizumab Q2W    73  23.3 FALSE        1
##  9   641 UNCOVER-2 Ixekizumab Q2W    72  27.9 FALSE        1
## 10   748 UNCOVER-2 Ixekizumab Q4W    80  23.9 TRUE         1
## 11   822 UNCOVER-2 Ixekizumab Q4W    72  28.4 TRUE         0
## 12  1134 UNCOVER-2 Placebo           76  27.8 TRUE         0
## # A tibble: 1,221 x 7
## # Groups:   X, bmi [1,221]
##        X trial     trt          age   bmi male  response
##    <int> <chr>     <chr>      <int> <dbl> <lgl>    <int>
##  1     1 UNCOVER-2 Etanercept    51  34.5 TRUE         0
##  2     2 UNCOVER-2 Etanercept    64  24.2 TRUE         1
##  3     3 UNCOVER-2 Etanercept    59  26.1 TRUE         1
##  4     4 UNCOVER-2 Etanercept    54  19.7 TRUE         0
##  5     5 UNCOVER-2 Etanercept    50  30.3 TRUE         0
##  6     6 UNCOVER-2 Etanercept    57  25.8 TRUE         1
##  7     7 UNCOVER-2 Etanercept    36  30.3 TRUE         0
##  8     8 UNCOVER-2 Etanercept    54  38.1 FALSE        1
##  9     9 UNCOVER-2 Etanercept    50  30.3 FALSE        0
## 10    10 UNCOVER-2 Etanercept    26  27.2 TRUE         1
## # … with 1,211 more rows